GHO Capital Acquires Genesis Research, a Pioneer in Tech-enabled Real-World Evidence and HEOR Services
Summary
Genesis optimizes drug development and evidences the clinical and commercial value of products via expert analysis, synthesis, communication and utilization of integrated Real-World Data (RWD). This advanced machine learning platform helps healthcare decision makers find high quality, targeted results faster, more efficiently and from an unprecedented breadth of sources. • Evidence for value and access technology (EVA) facilitates communication with internal stakeholders throughout a product’s lifecycle and provides a consistent approach to reimbursement and submission to national, regional, and local payers. With a broad base of blue-chip Pharmaceutical manufacturers and emerging Biotechnology companies, Genesis is an established leader and one of the largest operators within a highly fragmented sector. The Partners at GHO Capital, said, “The investment in Genesis follows years of work internally to identify market leading platforms with ambitious management teams in RWE and HEOR.